Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy: Molecular Therapy - Oncolytics
€ 14.00 · 4.9 (77) · In Magazzino
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte -based adoptive T cell therapy: Molecular Therapy - Oncolytics
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy, Molecular Cancer
Cancers, Free Full-Text
Enhancing CAR-T Cell Therapy with Functional Nucleic Acids
The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Immuno, Free Full-Text
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte -based adoptive T cell therapy: Molecular Therapy - Oncolytics
CAR-T cell therapy: current limitations and potential strategies
CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders - Cytotherapy
